Raphael Elage

Raphael Elage requested more details on the Q1 inventory increase and its expected trajectory, as well as clarification on the main drivers of capital expenditures during the quarter.

Answer

Executive Ramon Frutuoso Silva explained that inventory rose because production remained constant for efficiency while sell-in was reduced; he expects levels to normalize in Q2 and Q3. He detailed that major CapEx was directed towards the Jundiaí site for a pilot plant and oncology factory, and the Itapecerica plant expansion to internalize Takeda's production.

Raphael Elage from XP Inc. asked for more details on the increase in inventory during the quarter and the outlook for this line item. He also requested additional color on the company's CapEx investments.

Answer

Executive Ramon Frutuoso Silva explained that inventory of finished goods increased because production levels were maintained for efficiency while sell-in was reduced, but he expects levels to normalize in Q2 and Q3. He detailed that major CapEx was directed towards the Jundiaí site for a new pilot plant, an R&D lab, and an oncology factory, as well as an expansion at the Itapecerica plant.

Raphael Elage requested more details on the increase in inventory during the quarter and its expected behavior going forward, and also asked for specifics on capital expenditures (CapEx).

Answer

Executive Ramon Frutuoso Silva explained that inventory of finished goods increased because the plant maintained constant production speed despite the planned reduction in sell-in, and he expects levels to normalize in Q2 and Q3. He detailed that Q1 CapEx was focused on the Jundiaí site (pilot plant, R&D lab, oncology factory) and the expansion of the Itapecerica plant.

Raphael Elage requested more details on the increase in inventory during the quarter, its expected behavior going forward, and further clarification on capital expenditure (CapEx) investments.

Answer

Ramon Frutuoso Silva, an executive, explained that inventory of finished goods increased because production speed was maintained for efficiency despite the reduction in sell-in. He expects inventory levels to normalize in Q2 and Q3. Regarding CapEx, he detailed investments in the Jundiaí site for a pilot plant and oncology factory, and an expansion at the Itapecerica plant to internalize Takeda's production.